GSK takes stake in Spero in deal for experimental UTI treatment

Spero Therapeutics

22/09/2022 07:27

Sept 22 (Reuters) - British drugmaker GSK  GSK.L  said
on Thursday it would take a stake in Spero Therapeutics  SPRO.O 
as part of a licensing agreement for the U.S.-based drug
developer's experimental antibiotic for complicated urinary
tract infections.
    GSK will pay Spero $66 million upfront for the antibiotic
tebipenem HBr and buy $9 million of Spero shares, the companies
said in a joint statement.
 (Reporting by Amna Karimi in Bengaluru; Editing by Sriraj
Kalluvila)
 ((Amna.Karimi@thomsonreuters.com; +91 8083261226;))